Angle: Change Of Adviser

GUILDFORD, SURREY--(Marketwired - September 05, 2017) - Angle PLC (AIM: AGL) (OTCQX: ANPCY),

(AIM: AGL OTCQX: ANPCY)                                    5 September 2017

ANGLE plc ("the Company")

Change of Adviser

ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, is pleased to announce the appointment of finnCap Ltd as Nominated Adviser and Joint Broker with immediate effect. WG Partners remains Joint Broker to the Company.

For further information:

ANGLE plc                                          +44 1483 343434          
Andrew Newland, Chief Executive                                             
Ian Griffiths, Finance Director                                             
                                                                            
finnCap Ltd                                        +44 (0)20 7220 0500      
Corporate Finance - Adrian Hargrave, Simon Hicks,                           
 Kate Bannatyne                                                             
Corporate Broking - Alice Lane, Nikita Jain                                 
                                                                            
WG Partners                                                                 
Nigel Barnes                                       +44 (0) 203 705 9318     
Nigel Birks                                        +44 (0) 203 705 9316     
                                                                            
FTI Consulting                                                              
Simon Conway, Mo Noonan, Stephanie Cuthbert        +44 20 3727 1000         
Kimberly Ha (US)                                   +1 212 850 5612          

About ANGLE plc

ANGLE is a world-leading liquid biopsy company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.

ANGLE's cell separation technology is called the Parsortix™ system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the United States.

ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the-company/collaborators/

The analysis of the cells that can be harvested from patient blood with ANGLE's Parsortix system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.

The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi-billion dollar clinical market. The Parsortix system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness.

As well as cancer, the Parsortix technology has the potential for deployment with several other important cell types in the future.

ANGLE stock trades on the AIM market of the London Stock Exchange under the ticker symbol AGL and in New York on the OTC-QX under the ticker symbol ANPCY. For further information please visit: www.angleplc.com